This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Crooke S. T. and Bennett CF. (1996) Progress in antisense oligonucleotide therapeutics. Ann. Rev. Pharm.Tox. 36, 107–129.
Pasternak G. W. and Standifer K. M. (1995) Mapping of opioid receptors using antisense oligodeoxynucleotides: correlating their molecular biology and pharmacology. Trends Pharmacol. Sci. 16, 344–350.
Niggli E., Schwaller B., and Lipp P. (1996) Antisense oligodeoxynucleotides directed against the Na–Ca exchanger mRNA. Promising tools for studies on the cellular and molecular level. Ann. NY Acad. Sci. 779, 93–102.
Ramchandani S., MacLeod R. A., Pinard M., von Hoffe E., and Szyf M. (1997) Inhibition of tumorigenesis by a cytosine-DNA, methyltransferase, antisense oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA 94, 684–689.
Zhang R., Y. J., Shahinian H., Amin G., Lu Z., Liu T., Saag M.S., Temsamani Y., and Martin R. R. (1995) Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIVinfected subjects. Clin. Pharm. Ther. 58, 44–53.
Bishop, M. R., Iversen, P. L., Bayever, E., Shar, J. G., Greiner, T. C., Copple, et al. (1995) Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J. Clin. Oncol. 14, 1320–1326.
Agrawal, S (1996) Antisense oligonucleotides: towards clinical trials. Trends Biotech. 14, 376–378.
Tonkinson, J. L. and Stein, C. A. (1996) Antisense oligonucleotides as clinical therapeutic agents. Cancer Invest. 14, 64–65.
Dominski, Z. and Kole, R. (1993) Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA 90, 8673–8677.
Sierakowska, H., Sambade, M. J., Agrawal, S., and Kole, R. (1996) Repair of thalassemic human β-globin mRNA in mammalian cells by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA. 93, 12840–12844.
Weatherall, D. J. (1994) Thalassemias, in The Molecular Basis of Blood Diseases (Stamatoyannopoulos, G., et al., eds.), W.B. Saunders Philadelphia, pp. 157–205.
Mirabelli, C. K., and Crooke, S. T. (1993) Antisense oligonucleotides in the context of modern molecular drug discovery and development, in Antisense Research and Applications (Crooke, S. T. and Lebleu, B., eds.), CRC, Boca Raton, FL, pp. 7–35.
Furdon, P. F., Dominski, Z., and Kole, R. (1989) RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds. Nucleic Acids Res. 17, 9193–9204.
Sproat, B. S. and Lamond, A. I. (1993) 2′-O-alkyloligoribonucleotides, in Antisense Research and Applications (Crooke, S. T. and Lebleu, B., eds.), CRC, Boca Raton, FL, pp. 351–3
Zhang, R., Lu, Z., Zhao, H., Zhang, X., Diasio, R. B., Habus, I., et al. (1995) In vivo stability, disposition and metabolism of a “hybrid” oligonucleotide phosphorothioate in rats. Biochem. Pharm. 50, 545–556.
Hawley-Nelson, P., Ciccarone, V., Gebeyehu, G., Jessee, J., and Felgner, P. L. (1993) Lipofectamine reagent: a new, higher efficiency polycationic liposome transfection reagent. Focus 15, 73–79.
Schagger, H. and von Jagov, G. (1987) Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal. Biochem. 166, 368–379.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Humana Press Inc.
About this protocol
Cite this protocol
Sierakowska, H., Agrawal, S., Kole, R. (2000). Antisense Oligonucleotides as Modulators of Pre-mRNA Splicing. In: Kmiec, E.B. (eds) Gene Targeting Protocols. Methods in Molecular Biology™, vol 133. Humana Press. https://doi.org/10.1385/1-59259-215-5:223
Download citation
DOI: https://doi.org/10.1385/1-59259-215-5:223
Publisher Name: Humana Press
Print ISBN: 978-0-89603-360-3
Online ISBN: 978-1-59259-215-9
eBook Packages: Springer Protocols